A Random Walk Rule for Phase I Clinical Trials
DOI10.2307/2533975zbMATH Open0877.62075OpenAlexW2152155324WikidataQ73436225 ScholiaQ73436225MaRDI QIDQ4349992FDOQ4349992
Nancy Flournoy, William F. Rosenberger, Stephen D. Durham
Publication date: 27 August 1997
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://semanticscholar.org/paper/724fae826be4426069dbe377ed74456475e8db3d
Recommendations
up-and-down designsadaptive designsquantile estimationtoxicity studiessmall sample distribution theory
Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)
Cited In (27)
- Title not available (Why is that?)
- Individualized dosing for multiple ordered groups of patients
- Up-and-down experiments of first and second order
- A conversation with Nancy Flournoy
- A new look at evaluating MTD designs in cancer research
- Information in a two-stage adaptive optimal design
- A new design of the continual reassessment method
- On optimal designs for clinical trials: an updated review
- Operating characteristics of the standard phase I clinical trial design.
- Sequential design for binary dose-response experiments
- Continual reassessment method with multiple toxicity constraints
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- Derivation of Exact Distributions Following an Up-and-Down Design
- Bayesian Optimal Designs for Phase I Clinical Trials
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Properties of frequency distributions induced by general up-and-down methods for estimating quantiles
- Randomized group up and down experiments
- Adaptive clinical trial designs for phase I cancer studies
- A sequential design for maximizing the probability of a favourable response
- Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials
- Dose Finding Using the Biased Coin Up-and-Down Design and Isotonic Regression
- On the consistency of the continual reassessment method with multiple toxicity constraints
- Designs for Single- or Multiple-Agent Phase I Trials
- An application of reinforced urn processes to determining maximum tolerated dose
- Group up-and-down designs for dose-finding
- Stochastic approximation and modern model-based designs for dose-finding clinical trials
- Simple benchmark for complex dose finding studies
This page was built for publication: A Random Walk Rule for Phase I Clinical Trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4349992)
